The chimeric monoclonal TNF-α antibody infliximab is recommended by the ECCO in moderate to severe cases of IBD to induce clinical remission, when conventional therapy is unsuccessful (level 4) [10, 11]. Here, TNF is linked to inflammatory bowel disease.